Lilly's US Bamlanivimab Contract Raises Difficult Allocation Considerations

 
• By Jessica Merrill

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

Open red metal empty medicine cabinet hanging on a dark gray marble wall background
Availability of Lilly's antibody for COVID-19 will be limited • Source: Shutterstock

More from Pricing Debate

More from Market Access